Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma: Raritan, New Jersey Monday, November ...

Thalidomide was the first immunomodulatory agent approved for use in myeloma. Although highly active, it is associated with considerable toxicity, particularly in older patients. Lenalidomide ...

The following is a summary of “Evolving treatment landscape of multiple myeloma in Portugal: A nation-wide retrospective ...

As the hunt for effective cancer therapies intensifies, some scientists are turning back to look at old drugs in a new light.

The Thalidomide scandal of 1961 prompted an increase in the regulation and testing of drugs before licensing, with a new amendment to US Food and Drug Administration (FDA) rules demanding proof of ...

10月29日，渤健（Biogen）以高达14.5 亿美元的总金额与Neomorph开展研究合作，以发现和开发用于治疗阿尔茨海默病、罕见神经系统疾病和免疫疾病的多个分子胶降解剂。

As the hunt for effective cancer therapies intensifies, some scientists are turning back to look at old drugs in a new light. The anti-malarial ...

Other treatments include three immunomodulating agents, Fung explained. “[These] three immunomodulating agents are [Thalomid (thalidomide)], [Pomalyst (pomalidomide)] and [Revlimid (lenalidomide)],” ...

An antimalarial drug, in combination with drugs that target resistance mechanisms, could be used to treat cancer.

† Median OS not reached at 21 months for eight patients with primary PCL. CE: Cyclophosphamide, etoposide; dex: Dexamethasone; M-80: Intermediate-dose melphalan, dexamethasone; MP: Melphalan ...

Oct. 9, 2024 — Researchers have created a CRISPR-based rapid molecular diagnostic for two forms of leukemia that are driven by mutations that involve gene fusions. The technology accurately ...